137 related articles for article (PubMed ID: 16186807)
1. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia.
Césaire R; Olière S; Sharif-Askari E; Loignon M; Lézin A; Olindo S; Panelatti G; Kazanji M; Aloyz R; Panasci L; Bell JC; Hiscott J
Oncogene; 2006 Jan; 25(3):349-58. PubMed ID: 16186807
[TBL] [Abstract][Full Text] [Related]
2. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
3. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.
Oliere S; Arguello M; Mesplede T; Tumilasci V; Nakhaei P; Stojdl D; Sonenberg N; Bell J; Hiscott J
J Virol; 2008 Jun; 82(12):5735-49. PubMed ID: 18417567
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Ahmed M; Cramer SD; Lyles DS
Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
[TBL] [Abstract][Full Text] [Related]
5. Progression of a vesicular stomatitis virus infection in primary lymphocytes is restricted at multiple levels during B cell activation.
Schmidt MR; Gravel KA; Woodland RT
J Immunol; 1995 Sep; 155(5):2533-44. PubMed ID: 7650383
[TBL] [Abstract][Full Text] [Related]
6. Priming antiviral cytotoxic T lymphocytes: requirement for CD4+ cells is dependent on the antigen presenting cell in vivo.
Ciavarra RP; Tedeschi B
Cell Immunol; 1994 Aug; 157(1):132-43. PubMed ID: 7913664
[TBL] [Abstract][Full Text] [Related]
7. Superantigen-activated T cells redirected by a bispecific antibody inhibit vesicular stomatitis virus replication in vitro and in vivo.
Fernandez-Sesma A; Peluso RW; Bai X; Schulman JL; Levy DE; Moran TM
J Immunol; 1998 Feb; 160(4):1841-9. PubMed ID: 9469445
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of interferon alpha therapy in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Saito M; Nose H; Usuku K; Sabouri AH; Matsuzaki T; Izumo S; Arimura K; Osame M
J Neurol Sci; 2006 Jul; 246(1-2):37-43. PubMed ID: 16545396
[TBL] [Abstract][Full Text] [Related]
9. Vesicular stomatitis virus infection triggers apoptosis associated with decreased DeltaNp63alpha and increased Bax levels in the immortalized HaCaT keratinocyte cell line.
Megyeri K; Orosz L; Kemény L
Biomed Pharmacother; 2007 Jun; 61(5):254-60. PubMed ID: 17459650
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle requisite for vesicular stomatitis virus replication in T lymphocytes activated with concanavalin A.
Fujisawa H; Kumazawa Y; Ohtani A; Nishimura C
J Clin Lab Immunol; 1984 Jan; 13(1):41-6. PubMed ID: 6325697
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
[TBL] [Abstract][Full Text] [Related]
12. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
Nishiura Y; Nakamura T; Fukushima N; Nakamura H; Ida H; Aramaki T; Eguchi K
Antivir Ther; 2009; 14(4):533-42. PubMed ID: 19578238
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells.
Chen S; Ishii N; Ine S; Ikeda S; Fujimura T; Ndhlovu LC; Soroosh P; Tada K; Harigae H; Kameoka J; Kasai N; Sasaki T; Sugamura K
Int Immunol; 2006 Feb; 18(2):269-77. PubMed ID: 16361311
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway.
Ishikawa C; Matsuda T; Okudaira T; Tomita M; Kawakami H; Tanaka Y; Masuda M; Ohshiro K; Ohta T; Mori N
Br J Haematol; 2007 Feb; 136(3):424-32. PubMed ID: 17233845
[TBL] [Abstract][Full Text] [Related]
16. VSV-tumor selective replication and protein translation.
Barber GN
Oncogene; 2005 Nov; 24(52):7710-9. PubMed ID: 16299531
[TBL] [Abstract][Full Text] [Related]
17. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
18. Induction of IL-10- and IFN-gamma-producing T-cell responses by autoreactive T-cells expressing human T-cell leukemia virus type I Tax.
Takatsuka N; Hasegawa A; Takamori A; Shimizu Y; Kato H; Ohashi T; Amagasa T; Masuda T; Kannagi M
Int Immunol; 2009 Sep; 21(9):1089-100. PubMed ID: 19654198
[TBL] [Abstract][Full Text] [Related]
19. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.
Tumilasci VF; Olière S; Nguyên TL; Shamy A; Bell J; Hiscott J
J Virol; 2008 Sep; 82(17):8487-99. PubMed ID: 18579592
[TBL] [Abstract][Full Text] [Related]
20. Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.
Tezuka K; Okuma K; Kuramitsu M; Matsuoka S; Tanaka R; Tanaka Y; Hamaguchi I
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
